1. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout
- Author
-
Barry D. Quart, Zancong Shen, Scott Baumgartner, Bradley Kerr, Kimberly Manhard, and Li-Tain Yeh
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Gout ,medicine.drug_class ,Allopurinol ,Urinary system ,Therapeutics ,Urine ,Gastroenterology ,Gout Suppressants ,lesinurad ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,serum urate ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Hyperuricemia ,Xanthine oxidase inhibitor ,combination ,030203 arthritis & rheumatology ,Pharmacology ,Cross-Over Studies ,Dose-Response Relationship, Drug ,business.industry ,nutritional and metabolic diseases ,Lesinurad ,Middle Aged ,Triazoles ,xanthine oxidase inhibitor ,medicine.disease ,Uric Acid ,030104 developmental biology ,chemistry ,Thioglycolates ,Uric acid ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
The objective of the study was to evaluate the effect of lesinurad, a selective uric acid uptake inhibitor, alone and in combination with the xanthine oxidase inhibitor allopurinol, on serum uric acid and urinary urate excretion in patients with gout and hyperuricemia. A phase 1b, multicenter, open‐label, multiple‐dose study was carried out in patients with gout with serum uric acid ≥8 mg/dL following washout of urate‐lowering therapy. Patients were treated with allopurinol 300 mg/day alone in week 1; lesinurad 400 or 600 mg/day was added in week 2, followed by lesinurad 400 or 600 mg/day alone in week 3. Serum uric acid and urine uric acid were evaluated each week. Safety was assessed throughout the study. Lesinurad 400 or 600 mg/day added to allopurinol 300 mg/day reduced serum uric acid by 60% and 72%, respectively, versus allopurinol alone (37%) or lesinurad 400 mg/day (44%) or 600 mg/day (47%) alone. A 100% response rate of serum uric acid
- Published
- 2018